Skip to main content

The RheumNow Week in Review – 21 July 2017

Jul 21, 2017 7:34 am

Dr. Jack Cush reviews the news from the past week on 

  1. FDA accepts Pfizers NDA for Xeljanz (tofacitinib) as treatment for moderately to severely active ulcerative colitis
  2. FDA rejects Romosuzumab (anti-Sclerostin OP Rx) w/ a complete response letter asking for resubmission, more data
  3. RA ACPA+ have higher economic burden with MORE early DMARD use (71 vs 50%) & Biologic use (20 vs 12%); more MD visits; & more Total costs
  4. Mucosal immunity seen in at-risk RA (preclinical) people who had more IgA producing plasmablasts (39%) than established RA or normal controls(1%, 9%) 
  5. 7 patients with Active Refractory Takayasu arteritis treated with RTX showed mixed results - 3 achieved remission but 4 failed to respond to RTX.  
  6. Study of 38,924 shows dairy intake assoc with an increased risk of OA hip replacement (unrelated to age, BMI, smoking, activity
  7. 1979-2013 Septic arthritis in RA has increased and associated with more biologic use, polyarticular infections, MRSA (6% v 31%); but same outcomes
  8. Alcohol & Smoking assoc w/ 2 fold risk of Hand OA. but being overweight or obese is NOT.
  9. MTX has yet to be shown to benefit Osteoarthritis; but there is a new PROMOTE trial looking at pain reduction. Still enrolling.
  10. Zurampic 200mg + Uloric fails vs Uloric alone at achieving two primary endpoints SUA
  11. Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too 
  12. Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis 
  13. Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus 
  14. FDA Approves Tremfya (guselkumab) for Plaque Psoriasis


Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.